Equitable (EQH) Q1 2025 Earnings Transcript

Equitable Holdings reported Q1 non-GAAP operating earnings of $421 million, or $1.30 per share, down 7% year over year, with GAAP net income of $63 million, but underlying retirement, wealth, and AB flow trends remained solid. The main drag was a Protection Solutions loss driven by $80 million of elevated mortality claims, partially offset by $1.6 billion of retirement net inflows, $2 billion of Wealth Management inflows, and $2.7 billion of active net inflows at AllianceBernstein, whose operating earnings rose 19% with a 33.7% margin. Management reaffirmed $1.6 billion-$1.7 billion of 2025 free cash flow and $2 billion for 2027, while planning a 13% dividend increase, $500 million of incremental buybacks, and an extraordinary dividend after the mid-year life reinsurance close.

Analysis

EQH’s setup is less about a clean quarter than a forced de-risking of the equity story. The mortality miss is noisy, but the more important signal is that management is using the pain point to justify accelerating capital migration out of the least predictable earnings stream and into AB-linked economics and buybacks. That changes the mix: lower headline volatility, higher holdco optionality, and a larger share of value tied to asset-gathering businesses that benefit when advice demand rises in choppy markets.

The reinsurance deal is the real catalyst, not the quarterly print. Once capital is released, EQH can re-rate on the basis of distributable capital per share rather than statutory insurance earnings, especially if management executes the hinted extra repurchase on top of the planned payout. The second-order effect is that the market may start valuing AB ownership more like a control asset and less like an opaque GAAP drag, which mechanically tightens the discount-to-look-through-value.

The key risk is that the stock is still effectively a macro hybrid: if equities stay weak, both fee income and free cash flow likely stay pinned toward the low end of guidance for at least the next 1-2 quarters. That means the near-term squeeze is between a cleaner longer-term capital story and a still-messy earnings tape. The consensus may be underappreciating how quickly sentiment can flip once the life transaction closes, but overestimating how much April/May market volatility can be ignored before it hits flows and repurchase cadence.

Relative value is better than outright beta here. RGA benefits tactically from the mortality transfer and should show cleaner earnings with less capital strain, while EQH becomes a capital return story with embedded asset management leverage; the tradeoff is that EQH retains more exposure to market sentiment through AB and Wealth. The setup favors buying into weakness ahead of the transaction close, but only if you’re paid for a 1-2 quarter drawdown risk window.

Key Decisions for Investors

• Go long EQH on weakness with a 3-6 month horizon; thesis is re-rating into the mid-year reinsurance close plus incremental buyback visibility. Best entry is on any pullback tied to market volatility rather than fundamentals.
• Pair trade: long RGA / short EQH for the next 1-2 quarters if you want cleaner earnings quality and lower capital complexity while EQH still absorbs the last bits of mortality noise and market sensitivity.
• Sell near-dated EQH call spreads if implied vol remains elevated into the reinsurance close; the stock likely grinds higher on capital-return headlines, but upside is capped until the market sees actual repurchase execution.
• For more aggressive exposure, buy EQH Jan-2026 calls and finance by selling lower-strike puts only if you are willing to own through a market drawdown; this expresses the catalyst without paying full cash equity ahead of volatility.
• Do not chase the stock after strong market days; the better risk/reward is to accumulate on broad selloffs when the market is discounting fee pressure faster than the capital-release narrative.